Navigation Links
Cutting-edge vaccine research to be showcased at AAPS National Biotechnology Conference
Date:5/13/2010

ARLINGTON, VA (May 13, 2010) Novel vaccines for diseases ranging from the flu to HIV highlight a week's worth of biotechnology research at the American Association of Pharmaceutical Scientists' (AAPS) National Biotechnology Conference (NBC). Scientists from academia, industry, and government will gather at the Hilton San Francisco Union Square Sunday, May 16 -Thursday, May 20 to share research and advances in biotherapeutics.

Researchers from the University of Texas at Austin have developed a delivery system utilizing invasin as a targeting molecule to M cells as well as an agent that can enhance the patient's immune response. This formulation may be useful in developing countries due to its stable powder form, which reduces the need for trained personnel to administer the medication. This platform oral vaccine system being developed by Tarik Khan and Jennifer Maynard, Ph.D. in collaboration with Margaret Phillips and Nicholas Peppas, Sc.D., targets immune cells in the gut, and may be applied to a number of diseases including flu, whooping cough, and HIV.

"By vaccinating through the oral route you remove the pain and fear associated with vaccines, require less experienced personnel for administration, and do a better job of mimicking the natural process of infection," said Khan.

It is hoped that a vaccination system, such as the one developed by Khan and Maynard, will increase patient compliance, the overall vaccination rate, and allow for widespread distribution in the developing world where diseases such as the flu and HIV are particularly deadly. This study is currently being evaluated with a model antigen in the mouse model.

Powder-based vaccinations are also the focus of research being conducted by researchers from the Aeras Global TB Vaccine Foundation and Crucell pharmaceuticals. The study, "Stabilizing Formulations for Inhalable Powders of an Adenovirus 35-vectored Tuberculosis (TB) Vaccine," demonstrates that it is possible to produce a stable dry powder formulation of a TB vaccine suitable for mass vaccination in a one-step drying process. The powder formulation helps stabilize the vaccine so variations in temperature will not negatively affect its effectiveness or shelf life.

Recent clinical trials showed that the liquid Adenovirus 35-vectored TB vaccine was safe in healthy adults. A booster shot of this vaccine stimulated the immune system in a manner thought to be important for protection against TB, which included activation of CD4 and CD8 T-cells. Animal studies for the powder-based vaccine are being planned.

These studies and other novel research will be presented during a week of educational programming devoted to advancing health through biotherapeutics. Conference programming consists of a Plenary Session, symposia, roundtables, posters, hot topics, and concludes with two short courses. Additionally, the Exposition Hall will be hosting over 100 companies.


'/>"/>

Contact: Joseph Catapano
catapanoj@aaps.org
703-248-4772
American Association of Pharmaceutical Scientists
Source:Eurekalert

Related biology news :

1. Using green chemistry to deliver cutting-edge drugs
2. $10 million gift to support cutting-edge epigenome center at USC
3. UW launches cutting-edge DNA fin-printing project for salmon
4. Michael J. Fox Foundation Funds $1.1 Million for Cutting-edge Approaches to Parkinsons Disease
5. Resilience in an aging society: GSA showcases cutting-edge meeting topics
6. New edition of laboratory manual includes cutting-edge techniques to study gene regulation
7. Cutting-edge amfAR grants fight HIV/AIDS in the lab and on the phone
8. CHIs 5th Biomarker World Congress: Signature Event with Cutting-Edge Agenda
9. Healing wounds with lasers, vehicles that drive themselves, other cutting-edge optics
10. International Rett Syndrome Foundation awards $2M for cutting-edge Rett syndrome research
11. Global Rainmakers Brings Cutting-Edge Biometric Security Products to Reality
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... Valencell , the leading innovator in ... a third consecutive year of triple digit growth for ... with a 360 percent increase in companies who have ... driven by sales of its wrist and ear Benchmark™ ... technology for hearables for fitness and healthcare applications. ...
(Date:11/30/2016)... and WARSAW, Poland , Nov. 30, 2016 Not many ... of the most crucial aspects of recovery so we need to do it well. ... risks, including heart problems, high blood pressure, stroke, diabetes, and even cancer. ... and find a Christmas present that could help them to manage their sleep quality? ... ...
(Date:11/28/2016)... "The biometric system market ... The biometric system market is in the growth stage ... future. The biometric system market is expected to be ... CAGR of 16.79% between 2016 and 2022. Government initiative ... in smartphones, rising use of biometric technology in financial ...
Breaking Biology News(10 mins):
(Date:12/8/2016)... 8, 2016 Soligenix, Inc. (OTCQB: SNGX) (Soligenix ... developing and commercializing products to treat rare diseases where ... it will be hosting an Investor Webcast Event Friday, ... origins of innate defense regulators (IDRs) as a new ... mucositis and the recently announced and published Phase 2 ...
(Date:12/8/2016)... SAN DIEGO , Dec. 8, 2016 /PRNewswire/ ... ), a leading commercial provider of clinically actionable ... cancer patients, announces that clinical data featuring its ... concordance to tissue biopsy for the detection of ... The results from research sponsored by Sara Cannon ...
(Date:12/7/2016)... 2016 /PRNewswire/ - OncoQuest Inc. ("OncoQuest"), a biopharmaceutical ... immunotherapeutic products for the treatment of cancer, today ... Manufacturing Development Program with Cytovance Biologics ( ... oregovomab antibody product. Supported by recent positive interim ... in ovarian cancer patients, OncoQuest has engaged Cytovance ...
(Date:12/7/2016)... 7, 2016  Vyriad Inc. announced today the appointment ... Board of Directors. "We are delighted to ... business and develop our oncolytic viruses as the next ... Stephen Russell , MD, PhD, CEO of Vyriad. "Al ... vision and passion for making a difference for cancer ...
Breaking Biology Technology: